These findings suggest that activated ADAM15 may be associated with E-cadherin shedding in such patients, increasing cell signaling as well as decreasing cell-cell binding and thus allowing bladder cancer progression. This evidence concerns the gene ADAM15 and urinary bladder carcinoma.